Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
about
Time-Dependent Protection of CB2 Receptor Agonist in StrokeDesign and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligandThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsAn investigation into the structural determinants of cannabinoid receptor ligand efficacy.Differential regulation of behavioral tolerance to WIN55,212-2 by GASP1.Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.Cannabinoids and neuroinflammation.Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries.Efficacy in CB1 receptor-mediated signal transductionActivation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury painCannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development.Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site.Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors.Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.Modulation of neurotransmission by cannabinoids in the basal ganglia.Effects of repeated dosing with mechanistically distinct antinociceptive ligands in a rat model of neuropathic spinal cord injury pain.Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels.Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.Endocannabinoid signaling regulates spontaneous transmitter release from embryonic retinal amacrine cells.O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.Neuroanatomical distribution of cannabinoid receptor gene expression in the brain of the rough-skinned newt, Taricha granulosa.Early phytocannabinoid chemistry to endocannabinoids and beyond.Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
P2860
Q27302924-F4263527-F3A2-4E84-A6C5-220C989D0600Q28366135-1FEAD242-427F-4148-A7E8-53C89C521D72Q30486707-1670B872-BB92-46E2-A81F-1BBEA37AE5AFQ33861944-F90926BF-B382-4E36-B301-255152E4AD6EQ34191520-799F9F16-77E4-4D5C-9F6F-DB4343F2C18EQ34199610-E0B36375-BBDC-4339-B219-599524C925DDQ35046205-995C0AF0-74BE-47C7-BA56-CCD9C15D02EAQ35047182-83A6286C-3419-4DD9-9475-15D23A7F993AQ35047507-5B16C66D-4717-434F-9CAA-F8107721561CQ35175618-175D579E-A05E-41A3-96F8-5856FB29398EQ36734955-F04D73AE-E8D6-4F2E-A355-4F7E8D5E11CEQ36775155-C91F3FC7-C870-494A-9686-0093B12AD230Q37984087-3C48BD12-912F-49C9-92A4-3806388E3D85Q38429080-9F354D59-2D26-40EE-855F-F823EC81DDB5Q39633370-61E03866-4877-45D5-A625-6D4CAA96E117Q40602156-39531803-C823-4C94-9E0F-EBD62CEB1696Q40943005-60C6E101-1204-421A-9A2F-505D5A6BC56AQ41371378-661D91C2-FC38-4A3D-984C-DF26A9E20A49Q41692444-C8B34103-08EA-4BFA-8502-FDC03310B96DQ43038421-AA18FF59-30FD-42D1-ADCE-98E0DED83C51Q44060463-6A2D7A26-D87D-4A9D-9426-70863D78A123Q46075930-959C5327-DA22-4D3E-891B-F5BC7C0480BFQ46814567-2787B8DF-4BF5-4689-8070-A5605C267D69Q46895943-5108DC10-B22C-45E0-AF14-8F9A0D14D85BQ48062717-F0F320EA-E397-47D5-BC1D-212BF4E19AB2Q48198217-7664F930-6DD2-4170-8841-F257ADE2C897Q50652493-9110C80A-3F1E-4AF8-B063-9DD57C6161E4
P2860
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Characterization and distribut ...... r antagonist, in rodent brain.
@ast
Characterization and distribut ...... r antagonist, in rodent brain.
@en
Characterization and distribut ...... r antagonist, in rodent brain.
@nl
type
label
Characterization and distribut ...... r antagonist, in rodent brain.
@ast
Characterization and distribut ...... r antagonist, in rodent brain.
@en
Characterization and distribut ...... r antagonist, in rodent brain.
@nl
prefLabel
Characterization and distribut ...... r antagonist, in rodent brain.
@ast
Characterization and distribut ...... r antagonist, in rodent brain.
@en
Characterization and distribut ...... r antagonist, in rodent brain.
@nl
P2093
P921
P1433
P1476
Characterization and distribut ...... r antagonist, in rodent brain.
@en
P2093
J C Brelière
M Rinaldi-Carmona
P304
P356
10.1016/0024-3205(96)00085-9
P407
P577
1996-01-01T00:00:00Z